Other research groups also combined the CRISPR/Cas9 technology with FH patient-derived iPSCs to correct mutations in the LDLR or MTTP gene, aiming to restore the normal lipid levels in iHLCs. This evidence concerns the gene LDLR and familial hyperaldosteronism.